UPRO vs XBI
ProShares UltraPro S&P500 vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.88% for UPRO.
- • UPRO pays a higher dividend yield (0.80%).
Side-by-side metrics
| Metric | UPRO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.88% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.80% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $5.19B | $10.92B |
YTD return | 19.88% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 3.04 | 1.01 |
P/E ratio | 24.27 | — |
Last price | $142.56 | $156.41 |
Inception | — | — |
Issuer | ProShares | State Street |
UPRO top holdings
| IQMM | ProShares GENIUS Money Market ETF | 21.67% |
| AAPL | Apple Inc | 3.96% |
| NVDA | NVIDIA Corp | 3.90% |
| MSFT | Microsoft Corp | 3.05% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About UPRO
UPRO (ProShares UltraPro S&P500) is 3x leveraged daily performance of the S&P 500. Managed by ProShares, the fund carries $5.2B in assets under management, an expense ratio of 0.88%, a dividend yield of 0.80%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 21.7% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.